The Albéa Group is manufacturing some of the plastic parts required for NG Biotech's rapid diagnostic tests. NG Biotech has developed a solution to contribute to the fight against the COVID-19 pandemic with the development of a serological test. In just four weeks, Albéa in Plouhinec, Brittany (France), developed multi-cavity molds for the caps and lids of the NG Biotech cassette tests, Albéa shared in a news release.
The first industrializations were successfully completed at the end of December and production is now accelerating, in line with NG Biotech's commercial strategy, Albéa reported.
Cyrille Guégan, Manager of Albéa Plouhinec, stated in the release: “It is a great pride for the whole team to work on a project as meaningful as public health. In a chaotic economic context, managing to adapt and imagine new opportunities, while highlighting the site's technical expertise in record time, is extremely inspiring.”
Added Milovan Stankov-Pugès, CEO of NG Biotech: “The manufacture of plastic parts for our rapid tests in local supply chains with a partner based in Brittany responds to three challenges: to strengthen our industrial independence, to reduce our environmental impact thanks to a considerable reduction in transport, and to support activity and employment in the Breton plastics sector.”
The Brittany Region is project stakeholder. A subsidy for industrial development has helped the Plouhinec plant transform one of its machines to adapt it to the printing of cassette tests.